Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.
P. Moore, T. Moyo, T. Hermanus, P. Kgagudi, F. Ayres, Z. Makhado, J. Sadoff, M. Le Gars, G. van Roey, C. Crowther, N. Garrett, L.-G. Bekker, L. Morris, H. Schuitemaker, G. Gray
The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.
bioRxiv · Jun 9, 2021 · PreprintImmunology